XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaborative Arrangements and Licensing Agreements, Biogen (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue $ 225,250 $ 188,411 $ 344,748 $ 318,935  
Biogen [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue 138,159 $ 97,402 197,395 $ 167,903  
Deferred contract revenue $ 241,800   $ 241,800   $ 307,400
Biogen [Member] | Revenue [Member] | Strategic Partner [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Concentration percentage 61.00% 52.00% 57.00% 53.00%  
Biogen [Member] | Minimum [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Cumulative payments received $ 3,900,000   $ 3,900,000    
2013 Strategic Neurology [Member] | QALSODY [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Next payment to be achieved 10,000   10,000    
Revenue 20,000        
2012 Neurology [Member] | ION582 [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Revenue 30,000        
2012 Neurology [Member] | IONIS-MAPT [Member]          
Collaborative Arrangement and Licensing Agreement [Abstract]          
Next payment to be achieved $ 25,000   $ 25,000